Karyopharm is a leading pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions.
Karyopharm develops medicines targeting patients with cancer in both hematologic malignancies and solid tumors.
Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis.
Karyopharm is committed to supporting independent research, globally, as part of the development process for Karyopharm investigational drug candidates.
Data from Karyopharm’s investigational drug candidates have been highlighted in numerous scientific journals and medical conferences.